Cannabinoid type 1 receptor antagonists (rimonabant) for smoking cessation
about
Cannabinoids and Epilepsy.Pharmacology of nicotine: addiction, smoking-induced disease, and therapeuticsPrior exposure to THC increases the addictive effects of nicotine in rats.Recent advances in understanding nicotinic receptor signaling mechanisms that regulate drug self-administration behavior.Endogenous fatty acid ethanolamides suppress nicotine-induced activation of mesolimbic dopamine neurons through nuclear receptorsDo placebo response rates from cessation trials inform on strength of addictions?Cannabinoid-related agents in the treatment of anxiety disorders: current knowledge and future perspectives.Early cannabis use and DSM-IV nicotine dependence: a twin study.An algorithm for tailoring pharmacotherapy for smoking cessation: results from a Delphi panel of international experts.Tobacco and cannabis co-occurrence: does route of administration matter?The future of endocannabinoid-oriented clinical research after CB1 antagonists.Evidence for association between polymorphisms in the cannabinoid receptor 1 (CNR1) gene and cannabis dependenceHigh on habits.Mistic and TarCF as fusion protein partners for functional expression of the cannabinoid receptor 2 in Escherichia coli.Involvement of the endocannabinoid system in reward processing in the human brainTHC reduces the anticipatory nucleus accumbens response to reward in subjects with a nicotine addiction.
P2860
Q27336451-6F719125-45C1-431A-88AF-B982222310E2Q34157674-30DB0FEF-16BA-4E79-9589-D42A8A99E50CQ34322263-FC0E997A-781B-4142-B780-CC27EC3BFF2EQ35184641-656966A6-CB95-45A4-B0B7-373C85845660Q35202878-C70F3FEE-5891-4275-8F43-EE35AB9BDBF3Q35859923-95616D99-2C52-4159-AB45-8A42198613E3Q36953261-FE009436-BB3F-43A5-9C56-68EB3B6A3D95Q37000693-722E71E6-2841-4D19-8D2A-82B154059876Q37038523-BCAFC8CA-19B7-4976-BAD9-16DD2EEB3AA0Q37186971-4C70011E-99BE-495A-B118-0CEDEDDA08C3Q37226111-9D61EAEF-5FEA-4963-9407-BCD8C4EAEFB3Q37245374-7BDFAA7C-DC97-40A6-B9AB-60C2CA1DF7A7Q37395798-CF6AB274-C0BE-4008-9CA8-5CBCBD13C181Q38540669-0D9CF55B-0BF3-49D9-9FD1-0A95AEDE8412Q40670083-D234FFFD-7A1B-4932-84EA-6A74F066472BQ41489097-83299878-C806-47AA-965F-11308F37F1C4
P2860
Cannabinoid type 1 receptor antagonists (rimonabant) for smoking cessation
description
1996 nî lūn-bûn
@nan
1996 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
1996 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
1996年の論文
@ja
1996年論文
@yue
1996年論文
@zh-hant
1996年論文
@zh-hk
1996年論文
@zh-mo
1996年論文
@zh-tw
1996年论文
@wuu
name
Cannabinoid type 1 receptor antagonists (rimonabant) for smoking cessation
@ast
Cannabinoid type 1 receptor antagonists (rimonabant) for smoking cessation
@en
Cannabinoid type 1 receptor antagonists (rimonabant) for smoking cessation
@en-gb
Cannabinoid type 1 receptor antagonists (rimonabant) for smoking cessation
@nl
type
label
Cannabinoid type 1 receptor antagonists (rimonabant) for smoking cessation
@ast
Cannabinoid type 1 receptor antagonists (rimonabant) for smoking cessation
@en
Cannabinoid type 1 receptor antagonists (rimonabant) for smoking cessation
@en-gb
Cannabinoid type 1 receptor antagonists (rimonabant) for smoking cessation
@nl
prefLabel
Cannabinoid type 1 receptor antagonists (rimonabant) for smoking cessation
@ast
Cannabinoid type 1 receptor antagonists (rimonabant) for smoking cessation
@en
Cannabinoid type 1 receptor antagonists (rimonabant) for smoking cessation
@en-gb
Cannabinoid type 1 receptor antagonists (rimonabant) for smoking cessation
@nl
P921
P1476
Cannabinoid type 1 receptor antagonists (rimonabant) for smoking cessation
@en
P2093
P2860
P356
10.1002/14651858.CD005353.PUB2
P577
1996-09-01T00:00:00Z